SXRN not checked
Jiangsu Guiqiong Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “4 mg SXRN injection, intravenous infusion once daily. Dosing schedule: 5 consecutive dosing days followed by a 2-day break within a 21-day cycle. Eligible participants who complete the double-blind phase and meet predefined criteria may enter an open-label treatment phase and receive 4 mg SXRN injection following the same 21-day dosing regimen.”In the company’s words, NCT07890324 on ClinicalTrials.gov
- Tested for
- Cachexia-Anorexia Syndrome, Cachexia; Cancer
- Main trialPhase 2
- “This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia. This study comprises a double-blind treatment phase, followed by an open-label treatment phase for eligible participants upon completion of the double-blind phase.”In the company’s words, NCT07890324 on ClinicalTrials.gov
Other drugs for Cachexia-Anorexia Syndrome
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- PonsegromabPfizer · Phase 2/3
- VisugromabCatalYm GmbH · Phase 2/3
- RilogrotugAVEO Pharmaceuticals, Inc. · Phase 2/3
- DS010Dartsbio Pharmaceuticals Ltd. · Phase 1/2
- TCMCB07Endevica Bio · Phase 2
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Aug 2027 | A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026